<DOC>
	<DOCNO>NCT01733992</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability pharmacokinetics R348 eye drop patient dry eye disease .</brief_summary>
	<brief_title>A Safety , Tolerability Pharmacokinetics Study R932348 Eye Drops Patients With Dry Eye Disease</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled single multiple ascend dose study evaluate ocular tolerability , safety , pharmacokinetics R348 administer patient mild moderate keratoconjunctivitis sicca ( KCS ) .</detailed_description>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Mild moderate Keratoconjunctivitis Sicca . A correct visual acuity eye 20/40 well . An intraocular pressure &lt; 21 mm Hg difference eye &lt; 6 mm Hg . History evidence ocular infection , inflammation , conjunctivitis within 2 month prior first dose day . History evidence blepharitis require use antibiotic eye scrub within 2 month prior first dose day . History herpes simplex keratitis time . Current ocular allergy symptom . Recent use eye medication steroid cyclosporine Refractive eye surgery within 12 month first dose day . Other eye surgery within 4 month first dose day . Current use contact lenses discontinuation contact lens use within 2 week first dose day . Receipt blood blood product within 90 day prior first dose day . Participation clinical study within 30 day prior first dose day . History disease , currently significant illness abnormal laboratory finding determine study doctor . Positive hepatitis B , hepatitis C HIV . Smoked regularly within 12 month first dose day . History substance abuse , drug addiction alcoholism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>